Published in Amyotroph Lateral Scler on November 20, 2009
Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine (2015) 0.83
Exercise and amyotrophic lateral sclerosis. Neurol Sci (2012) 0.81
Inspiratory muscle training to enhance recovery from mechanical ventilation: a randomised trial. Thorax (2016) 0.79
Physiotherapy secretion removal techniques in people with spinal cord injury: a systematic review. J Spinal Cord Med (2010) 0.77
Amyotrophic lateral sclerosis and the neuroprotective potential of exercise. J Physiol (2009) 0.77
Respiratory training in an individual with amyotrophic lateral sclerosis. Ann Clin Transl Neurol (2016) 0.75
Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature. Orphanet J Rare Dis (2017) 0.75
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Guillain-Barré syndrome: an update. J Clin Neurosci (2009) 2.46
Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20
Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08
Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve (2013) 2.00
Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94
Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.75
Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. J Neuroophthalmol (2005) 1.63
Panic attacks and perception of inspiratory resistive loads in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 1.62
Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol (2011) 1.59
Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol (2011) 1.55
Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54
Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52
Water-based exercise in COPD with physical comorbidities: a randomised controlled trial. Eur Respir J (2012) 1.52
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50
Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol (2008) 1.49
Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47
Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol (2010) 1.47
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44
Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust (2005) 1.42
Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clin Neurophysiol (2010) 1.41
Scurvy and stroke - is there an association? Med J Aust (2010) 1.40
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Neurotoxic marine poisoning. Lancet Neurol (2005) 1.33
Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31
Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve (2007) 1.30
Neural drive to human genioglossus in obstructive sleep apnoea. J Physiol (2007) 1.28
Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol (2009) 1.27
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22
Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22
Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med (2009) 1.19
Respiratory Movement of Upper Airway Tissue in Obstructive Sleep Apnea. Sleep (2013) 1.18
Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol (2010) 1.18
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 1.17
Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17
Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One (2012) 1.15
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry (2012) 1.14
Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain (2008) 1.10
FOSMN syndrome: novel insight into disease pathophysiology. Neurology (2012) 1.10
How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2010) 1.09
Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotroph Lateral Scler (2012) 1.08
Firing probability and mean firing rates of human muscle vasoconstrictor neurones are elevated during chronic asphyxia. J Physiol (2010) 1.07
Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.05
Changes in human sensory axonal excitability induced by focal nerve compression. J Physiol (2010) 1.04
Altered motor nerve excitability in end-stage kidney disease. Brain (2005) 1.02
Nerve function and dysfunction in acute intermittent porphyria. Brain (2008) 1.00
Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00
Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Prefer Adherence (2012) 1.00
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.98
Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98
Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry (2009) 0.95
Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain (2010) 0.95
Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol (2014) 0.94
Axonal changes in spinal cord injured patients distal to the site of injury. Brain (2007) 0.94
Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. J Physiol (2008) 0.94
Neurological complications of chronic kidney disease. Nat Rev Neurol (2009) 0.93
Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant (2004) 0.93
Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain (2013) 0.92
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One (2011) 0.92
Diaphragm length and neural drive after lung volume reduction surgery. Am J Respir Crit Care Med (2005) 0.92
Tongue and lateral upper airway movement with mandibular advancement. Sleep (2013) 0.92
Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry (2013) 0.92
Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler (2011) 0.91
Assessment of disease progression in motor neuron disease. Lancet Neurol (2005) 0.91
Congenital myasthenic syndromes. J Clin Neurosci (2008) 0.90
Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology (2013) 0.90
Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. J Clin Neurosci (2009) 0.90
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr (2012) 0.89
Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst (2008) 0.88
Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve (2010) 0.88
Puffer fish poisoning: a potentially life-threatening condition. Med J Aust (2002) 0.88
The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res (2009) 0.87
Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). J Clin Neurosci (2006) 0.87
Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS One (2011) 0.87
The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol (2013) 0.86
Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol (2009) 0.86
The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics (2015) 0.86
Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology (2013) 0.85
Wernicke's encephalopathy presenting with upbeating nystagmus. J Clin Neurosci (2002) 0.85
Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs (2010) 0.85
Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle Nerve (2014) 0.85
The relationship between cortical and spinal hyperexcitability and clinical disease severity in stiff-man syndrome. Parkinsonism Relat Disord (2012) 0.85
Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. PLoS One (2013) 0.85
Cortical dysfunction underlies disability in multiple sclerosis. Mult Scler (2011) 0.84
In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. Brain (2012) 0.84
Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. J Clin Neurosci (2006) 0.84
Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain (2011) 0.84
The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer (2007) 0.84
Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. J Neurol (2015) 0.84
Diaphragm length during tidal breathing in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 0.83
Plasticity of lower limb motor axons after cervical cord injury. Clin Neurophysiol (2008) 0.83
Motor cortex excitability in acute cerebellar infarct. Cerebellum (2013) 0.83